Fulgent Genetics, Inc. (FLGT)
| Previous close | 21.49 |
| Open | 21.43 |
| Bid | 21.41 x 400 |
| Ask | 21.62 x 400 |
| Day's range | 21.43 - 21.78 |
| 52-week range | 19.88 - 44.09 |
| Volume | |
| Avg. volume | 218,983 |
| Market cap | 643.971M |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Fulgent Reports First Quarter 2024 Financial Results
EL MONTE, Calif., May 03, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.
- Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif., April 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.
- Business Wire
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
EL MONTE, Calif., February 28, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.
